£2.0M
Epidarex Capital led the Series A round for the drug toxicity testing specialist.
Clyde Biosciences develops technology to evaluate drug toxicity.
Clyde Biosciences is a life sciences company originating from the University of Glasgow that evaluates drug toxicity for pharmaceutical developers.
Cash at bank
Net assets
Shareholders' funds
Employees
Cash, assets and headcount from Clyde Biosciences's latest Companies House filing — with year-on-year movement, free with a Winfred account.
Margaret Craig
Co-founder and CEO
Epidarex Capital led the Series A round for the drug toxicity testing specialist.